{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:37:19Z","timestamp":1783593439198,"version":"3.55.0"},"reference-count":92,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1005974"],"award-info":[{"award-number":["OPP1005974"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0218649","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T20:05:17Z","timestamp":1562184317000},"page":"e0218649","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2075-3179","authenticated-orcid":true,"given":"Ume L.","family":"Abbas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Glaubius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,7,3]]},"reference":[{"key":"ref1","unstructured":"UNAIDS data 2018. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.unaids.org\/en\/resources\/documents\/2018\/unaids-data-2018\" xlink:type=\"simple\">http:\/\/www.unaids.org\/en\/resources\/documents\/2018\/unaids-data-2018<\/ext-link>. (Accessed 30 December 2018)."},{"key":"ref2","unstructured":"UNAIDS. On the fast-track to end AIDS: UNAIDS 2016\u20132021 Strategy. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/20151027_UNAIDS_PCB37_15_18_EN_rev1.pdf\" xlink:type=\"simple\">http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/20151027_UNAIDS_PCB37_15_18_EN_rev1.pdf<\/ext-link> (Accessed 30 December 2018). 2015."},{"key":"ref3","unstructured":"World Health Organization. HIV drug resistance report 2017. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/hiv\/pub\/drugresistance\/hivdr-report-2017\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/hiv\/pub\/drugresistance\/hivdr-report-2017\/en\/<\/ext-link> (Accessed 30 December 2018). 2017."},{"key":"ref4","unstructured":"World Health Organization. Global action plan on HIV drug resistance 2017\u20132021. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.who.int\/hiv\/pub\/drugresistance\/hivdr-action-plan-2017-2021\/en\/\" xlink:type=\"simple\">https:\/\/www.who.int\/hiv\/pub\/drugresistance\/hivdr-action-plan-2017-2021\/en\/<\/ext-link>. (Accessed: 30 December 2018). Geneva 2017."},{"key":"ref5","unstructured":"World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.who.int\/hiv\/pub\/guidelines\/ARV2018update\/en\/\" xlink:type=\"simple\">https:\/\/www.who.int\/hiv\/pub\/guidelines\/ARV2018update\/en\/<\/ext-link> (Accessed 30 Dec 2018). Geneva 2018."},{"key":"ref6","unstructured":"World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.who.int\/hiv\/pub\/guidelines\/hivdr-guidelines-2017\/en\/\" xlink:type=\"simple\">https:\/\/www.who.int\/hiv\/pub\/guidelines\/hivdr-guidelines-2017\/en\/<\/ext-link> (Accessed 30 December 2018). Geneva 2017."},{"key":"ref7","article-title":"South African national HIV prevalence, incidence and behaviour survey, 2012","author":"O Shisana","year":"2014"},{"issue":"Suppl 4","key":"ref8","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1093\/cid\/cir1017","article-title":"Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005\u20132009","volume":"54","author":"GM Hunt","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1089\/aid.2011.0284","article-title":"Primary drug resistance in South Africa: data from 10 years of surveys","volume":"28","author":"J Manasa","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/jmv.22143","article-title":"Resistance to antiretroviral drugs in newly diagnosed, young treatment-naive HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa","volume":"83","author":"R Parboosing","year":"2011","journal-title":"J Med Virol"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"e59787","DOI":"10.1371\/journal.pone.0059787","article-title":"Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009)","volume":"8","author":"UM Parikh","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/infdis\/jiw491","article-title":"Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa","volume":"214","author":"K Steegen","year":"2016","journal-title":"J Infect Dis"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"e0166305","DOI":"10.1371\/journal.pone.0166305","article-title":"Moderate levels of pre-treatment HIV-1 antiretroviral drug resistance detected in the first south african national survey","volume":"11","author":"K Steegen","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/jac\/dkw358","article-title":"HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa","volume":"72","author":"K Steegen","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","article-title":"Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa","volume":"71","author":"TS Boender","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1093\/jac\/dkx252","article-title":"Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa","volume":"72","author":"GM Hunt","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/aid.2018.0202","article-title":"Moderate-to-high levels of pretreatment HIV drug resistance in KwaZulu-Natal province, South Africa","volume":"35","author":"B Chimukangara","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref18","first-page":"648","article-title":"Discrete-event system simulation","author":"J Banks","year":"2009"},{"key":"ref19","article-title":"Simulation modeling and analysis","author":"A Law","year":"2000"},{"key":"ref20","article-title":"Theory of modeling and simulation","author":"B Zeigler","year":"1976"},{"key":"ref21","first-page":"372","article-title":"Multifacetted modelling and discrete event simulation","author":"BP Zeigler","year":"1984"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1016\/j.ifacol.2017.08.672","article-title":"From discrete event simulation to discrete event specified systems (DEVS)","volume":"50","author":"BP Zeigler","year":"2017","journal-title":"IFAC-PapersOnLine"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Ingalls RG. Introduction to simulation. Proceedings of the 2013 Winter Simulation Conference: Simulation: Making decisions in a complex world; Washington, D.C. 2676019: IEEE Press; 2013. p. 291\u2013305.","DOI":"10.1109\/WSC.2013.6721428"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/0272989X12455462","article-title":"Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4","volume":"32","author":"J Karnon","year":"2012","journal-title":"Med Decis Making"},{"key":"ref25","unstructured":"Glynn PW. On the role of generalized semi-Markov processes in simulation output analysis. Proceedings of the 15th conference on Winter simulation\u2014Volume 1; Arlington, Virginia, USA. 801471: IEEE Press; 1983. p. 39\u201344."},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1145\/132277.132281","article-title":"Structural and behavioral equivalence of simulation models","volume":"2","author":"E Y\u00fccesan","year":"1992","journal-title":"ACM Trans Model Comput Simul"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1749-6632.2001.tb02756.x","article-title":"New data and tools for integrating discrete and continuous population modeling strategies","volume":"954","author":"JS Koopman","year":"2001","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0025-5564(00)00028-6","article-title":"Analysis and simulation of a stochastic, discrete-individual model of STD transmission with partnership concurrency","volume":"166","author":"SE Chick","year":"2000","journal-title":"Math Biosci"},{"issue":"5\/6","key":"ref29","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10955-009-9814-1","article-title":"More is the same; phase transitions and mean field theories","volume":"137","author":"LP Kadanoff","year":"2009","journal-title":"Journal of Statistical Physics"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/imamat\/hxs001","article-title":"From exact stochastic to mean-field ODE models: a new approach to prove convergence results","volume":"78","author":"PL Simon","year":"2013","journal-title":"IMA Journal of Applied Mathematics"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/cid\/ciw321","article-title":"Cost-effectiveness of injectable preexposure prophylaxis for HIV prevention in South Africa","volume":"63","author":"RL Glaubius","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref32","article-title":"Deciphering the effects of injectable pre-exposure prophylaxis for combination HIV prevention","author":"RL Glaubius","year":"2016","journal-title":"Open Forum Infectious Diseases"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"e25282","DOI":"10.1002\/jia2.25282","article-title":"Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness","volume":"22","author":"R Glaubius","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0272989X9401400107","article-title":"Determining transition probabilities: confusion and suggestions","volume":"14","author":"DK Miller","year":"1994","journal-title":"Med Decis Making"},{"issue":"25","key":"ref35","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/j100540a008","article-title":"Exact stochastic simulation of coupled chemical reactions","volume":"81","author":"DT Gillespie","year":"1977","journal-title":"J Phys Chem"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1063\/1.1378322","article-title":"Approximate accelerated stochastic simulation of chemically reacting systems","volume":"115","author":"DT Gillespie","year":"2001","journal-title":"J Chem Phys"},{"key":"ref37","first-page":"1368","article-title":"The C++ programming language","author":"B Stroustrup","year":"2013"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1541-0420.2010.01399.x","article-title":"Estimating and projecting trends in HIV\/AIDS generalized epidemics using incremental mixture importance sampling","volume":"66","author":"AE Raftery","year":"2010","journal-title":"Biometrics"},{"key":"ref39","first-page":"272","article-title":"Practical handbook of curve fitting","author":"S Arlinghaus","year":"1994"},{"issue":"Suppl 2","key":"ref40","doi-asserted-by":"crossref","first-page":"ii28","DOI":"10.1136\/sti.2010.044255","article-title":"Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy","volume":"86","author":"M Mahy","year":"2010","journal-title":"Sex Transm Infect"},{"key":"ref41","unstructured":"South Africa National AIDS Council. National strategic plan on HIV, STIs and TB, 2012\u20132016. Pretoria: SANAC; 2012."},{"issue":"18","key":"ref42","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1097\/01.aids.0000432444.30308.2d","article-title":"The long-term efficacy of medical male circumcision against HIV acquisition","volume":"27","author":"SD Mehta","year":"2013","journal-title":"AIDS"},{"key":"ref43","unstructured":"South Africa National Department of Health. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. Pretoria: DoH; 2014."},{"key":"ref44","unstructured":"South African National AIDS Council (SANAC). South Africa&apos;s national strategic plan for HIV, TB and STIs 2017\u20132022. 2017."},{"key":"ref45","unstructured":"Joint United Nations Programme on HIV\/AIDS. Ending AIDS: Progress towards the 90-90-90 targets. Geneva: Joint United Nations Programme on HIV\/AIDS; 2017."},{"key":"ref46","unstructured":"Joint United Nations Programme on HIV\/AIDS. Fast-Track: ending the AIDS epidemic by 2030. Geneva: Joint United Nations Programme on HIV\/AIDS; 2014."},{"issue":"6","key":"ref47","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"MS Cohen","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"ref48","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2013.03.013","article-title":"Impact of definitions of loss to follow-up (LTFU) in antiretroviral therapy program evaluation: variation in the definition can have an appreciable impact on estimated proportions of LTFU","volume":"66","author":"AT Grimsrud","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"e1001418","DOI":"10.1371\/journal.pmed.1001418","article-title":"Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies","volume":"10","author":"LF Johnson","year":"2013","journal-title":"PLoS Med"},{"issue":"4","key":"ref50","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/QAD.0b013e32835c12f9","article-title":"Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting","volume":"27","author":"K Clouse","year":"2013","journal-title":"AIDS"},{"issue":"9672","key":"ref51","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(09)60612-7","article-title":"Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies","volume":"373","author":"JAC Sterne","year":"2009","journal-title":"Lancet"},{"issue":"Suppl 2","key":"ref52","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/infdis\/jit107","article-title":"Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings","volume":"207","author":"MC Hosseinipour","year":"2013","journal-title":"J Infect Dis"},{"issue":"3","key":"ref53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1473-3099(09)70328-7","article-title":"Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review","volume":"10","author":"RE Barth","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","article-title":"Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study","volume":"12","author":"RL Hamers","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"ref55","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","article-title":"Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis","volume":"305","author":"JZ Li","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"ref56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/cit627","article-title":"Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-Saharan Africa and southeast Asia","volume":"58","author":"AF Aghokeng","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/cid\/cis254","article-title":"Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies","volume":"54","author":"RL Hamers","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref58","unstructured":"World Health Organization. WHO HIV drug resistance report 2012. Geneva: World Health Organization; 2012."},{"issue":"8","key":"ref59","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/infdis\/jiq167","article-title":"Differential persistence of transmitted HIV-1 drug resistance mutation classes","volume":"203","author":"V Jain","year":"2011","journal-title":"J Infect Dis"},{"issue":"1","key":"ref60","doi-asserted-by":"crossref","first-page":"e14638","DOI":"10.1371\/journal.pone.0014638","article-title":"Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity","volume":"6","author":"AC Paquet","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"ref61","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.aids.0000216370.69066.7f","article-title":"Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy","volume":"20","author":"S Palmer","year":"2006","journal-title":"AIDS"},{"issue":"2","key":"ref62","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1128\/AAC.48.2.644-647.2004","article-title":"Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy","volume":"48","author":"M Wirden","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref63","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/infdis\/jit345","article-title":"Persistence of HIV-1 transmitted drug resistance mutations","volume":"208","author":"H Castro","year":"2013","journal-title":"J Infect Dis"},{"issue":"9","key":"ref64","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1086\/496892","article-title":"Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection","volume":"192","author":"SG Deeks","year":"2005","journal-title":"J Infect Dis"},{"issue":"1","key":"ref65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/aid.2008.0159","article-title":"Dynamics of NRTI resistance mutations during therapy interruption","volume":"25","author":"M Trignetti","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6193","key":"ref66","doi-asserted-by":"crossref","first-page":"1254031","DOI":"10.1126\/science.1254031","article-title":"HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck","volume":"345","author":"JM Carlson","year":"2014","journal-title":"Science"},{"issue":"1","key":"ref67","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000433239.01611.52","article-title":"Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study","volume":"28","author":"BE Nichols","year":"2014","journal-title":"AIDS"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-4690-6-14","article-title":"Effects of the K65R and K65R\/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance","volume":"6","author":"HT Xu","year":"2009","journal-title":"Retrovirology"},{"issue":"5","key":"ref69","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"ref70","doi-asserted-by":"crossref","first-page":"e0145772","DOI":"10.1371\/journal.pone.0145772","article-title":"HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing","volume":"10","author":"SY Rhee","year":"2015","journal-title":"PLoS One"},{"key":"ref71","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs For treating and preventing HIV infection: recommendations for a public health approach. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf?ua=1\" xlink:type=\"simple\">http:\/\/apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf?ua=1<\/ext-link> (Accessed: July 22, 2018). 2016."},{"issue":"6","key":"ref72","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/S2352-3018(16)30011-X","article-title":"Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study","volume":"3","author":"AM La Rosa","year":"2016","journal-title":"Lancet HIV"},{"issue":"1","key":"ref73","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAI.0000000000001883","article-title":"Third-line antiretroviral therapy program in the South African public sector: cohort description and virological outcomes","volume":"80","author":"M Moorhouse","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref74","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). UNAIDS Data 2017. 2017."},{"issue":"4","key":"ref75","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/QAI.0b013e3181bcdac1","article-title":"High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa","volume":"53","author":"MP Fox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"ref76","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/infdis\/jit411","article-title":"Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch","volume":"209","author":"V Johnston","year":"2014","journal-title":"J Infect Dis"},{"issue":"2","key":"ref77","doi-asserted-by":"crossref","first-page":"e56088","DOI":"10.1371\/journal.pone.0056088","article-title":"Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa","volume":"8","author":"MA Luque-Fernandez","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"ref78","first-page":"239","article-title":"A comparison of three methods for selecting values of input variables in the analysis of output from a computer code","volume":"21","author":"MD McKay","year":"1979","journal-title":"Technometrics"},{"key":"ref79","unstructured":"(PEPFAR) Smith S. Dolutegravir \/ TLD roll out in South Africa. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.sahivsoc2018.co.za\/wp-content\/uploads\/2018\/11\/17_Steven-Smith_SAHIVCS-Oct-2018-oct-26-draft.pdf\" xlink:type=\"simple\">http:\/\/www.sahivsoc2018.co.za\/wp-content\/uploads\/2018\/11\/17_Steven-Smith_SAHIVCS-Oct-2018-oct-26-draft.pdf<\/ext-link>. 2017."},{"issue":"1","key":"ref80","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4102\/sajhivmed.v19i1.917","article-title":"Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy","volume":"19","author":"MA Moorhouse","year":"2018","journal-title":"South Afr J HIV Med"},{"key":"ref81","unstructured":"Moyo S, Hunt G, Khangelani Z, Zungu NP, Marinda E, Mabaso M, et al. HIV drug resistance in South Africa: results from a population-based household survey. The Conference on Retroviruses and Opportunistic Infections (CROI); March 4\u20137; Seattle, Washington2019."},{"issue":"2","key":"ref82","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(14)00061-7","article-title":"Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis","volume":"2","author":"MA Boyd","year":"2015","journal-title":"Lancet HIV"},{"issue":"8","key":"ref83","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial","volume":"4","author":"NI Paton","year":"2017","journal-title":"Lancet HIV"},{"issue":"2","key":"ref84","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/infdis\/jit150","article-title":"Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa","volume":"208","author":"UL Abbas","year":"2013","journal-title":"J Infect Dis"},{"issue":"9","key":"ref85","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix089","article-title":"Impact of HIV Drug Resistance on HIV\/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa","volume":"215","author":"AN Phillips","year":"2017","journal-title":"J Infect Dis"},{"issue":"9","key":"ref86","doi-asserted-by":"crossref","first-page":"e41212","DOI":"10.1371\/journal.pone.0041212","article-title":"Universal access to HIV treatment versus universal &apos;test and treat&apos;: transmission, drug resistance &amp; treatment costs","volume":"7","author":"BG Wagner","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"ref87","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S2352-3018(17)30190-X","article-title":"Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study","volume":"5","author":"AN Phillips","year":"2018","journal-title":"Lancet HIV"},{"issue":"2","key":"ref88","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/S2352-3018(18)30317-5","article-title":"Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study","volume":"6","author":"AN Phillips","year":"2019","journal-title":"Lancet HIV"},{"issue":"7","key":"ref89","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1016\/S2352-3018(18)30093-6","article-title":"Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research","volume":"5","author":"J Dorward","year":"2018","journal-title":"Lancet HIV"},{"issue":"12","key":"ref90","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial","volume":"4","author":"I Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.meegid.2016.06.047","article-title":"Differences among HIV-1 subtypes in drug resistance against integrase inhibitors","volume":"46","author":"YS Han","year":"2016","journal-title":"Infect Genet Evol"},{"issue":"4","key":"ref92","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/QAI.0000000000001116","article-title":"HIV-1 drug resistance by ultra-deep sequencing following short course zidovudine, single-dose nevirapine, and single-dose tenofovir with emtricitabine for prevention of mother-to-child transmission","volume":"73","author":"R Samuel","year":"2016","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0218649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T08:17:57Z","timestamp":1589012277000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0218649"}},"subtitle":[],"editor":[{"given":"Richard John","family":"Lessells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,7,3]]},"references-count":92,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0218649","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,3]]}}}